Cargando…
Burden of established cardiovascular disease in people with type 2 diabetes and matched controls: Hospital‐based care, days absent from work, costs and mortality
AIMS: To assess hospital‐based care, work absence, associated costs, and mortality in patients with type 2 diabetes with and without established cardiovascular disease (eCVD) compared to matched controls. MATERIALS AND METHODS: In a population‐based cohort study, we analysed individual‐level data fr...
Autores principales: | Persson, Sofie, Nilsson, Kristoffer, Karlsdotter, Kristina, Skogsberg, Josefin, Gustavsson, Staffan, Jendle, Johan, Steen Carlsson, Katarina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10098921/ https://www.ncbi.nlm.nih.gov/pubmed/36371525 http://dx.doi.org/10.1111/dom.14919 |
Ejemplares similares
-
Model‐based predictions on health benefits and budget impact of implementing empagliflozin in people with type 2 diabetes and established cardiovascular disease
por: Nilsson, Kristoffer, et al.
Publicado: (2022) -
Disease Burden and Healthcare Costs for T2D Patients With and Without Established Cardiovascular Disease in Sweden: A Retrospective Cohort Study
por: Bernfort, Lars, et al.
Publicado: (2020) -
Costs of diabetes complications: hospital-based care and absence from work for 392,200 people with type 2 diabetes and matched control participants in Sweden
por: Andersson, Emelie, et al.
Publicado: (2020) -
Economic burden of atherosclerotic cardiovascular disease: a matched case–control study in more than 450,000 Swedish individuals
por: Steen Carlsson, Katarina, et al.
Publicado: (2023) -
Empagliflozin reduces cardiorenal events, healthcare resource use and mortality in Sweden compared to dipeptidyl peptidase‐4 inhibitors: Real world evidence from the Nordic EMPRISE study
por: Nyström, Thomas, et al.
Publicado: (2022)